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Abstract
Astrocytes are highly responsive to changes in their microenvironment, and undergo 
prominent functional alterations in pathological conditions, a process called astroglio-
sis. In such conditions, astrocytes can gain immune cell-like functions, form glial scars 
and promote brain repair and regeneration. However, astrogliosis can also contribute to 
disease pathogenesis by exacerbating inflammation and perturbing the normal physi-
ological functions of astrocytes. The IKK/NF-κB signaling system is a master regulator of 
inflammation, cell survival and differentiation, which also controls astrocyte functions, in 
particular their responses to pathological conditions. Activation of IKK/NF-κB signaling 
in astrocytes is a key driver of neuroinflammation and astrogliosis, which can interfere 
with normal brain development and homeostasis and can aggravate various central ner-
vous system (CNS) pathologies. Besides IKK/NF-κB signaling, several other signaling 
pathways regulate pathophysiological responses of astrocytes, in particular hypertro-
phy, proliferation and the reactivation of neural stem cell-like properties of astrocytes. 
Further dissection of the role of these signaling pathways in the control of physiological 
functions and pathophysiological plasticity of astrocytes will reveal new insights into 
the pathogenesis of neurological diseases and might indicate new neuroprotective and 
regenerative therapeutic approaches.
Keywords: NF-kappa B, astrocytes, neuroinflammation, astrogliosis, 
neurodegeneration, brain development, brain homeostasis, signal transduction
1. Introduction
Astroglial cells, which comprise one of the major cell populations in the central nervous 
system (CNS), show a remarkable morphological and functional diversity and they are 
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highly important for brain development and homeostasis. For example, prototypical paren-
chymal astrocytes regulate the local cerebral blood flow and the transport of metabolites 
through the blood-brain-barrier (BBB) according to local demand [1]. These metabolites 
are then converted by astrocytes to metabolites required by neurons and other cells in the 
brain parenchyma [1]. Astrocyte also directly contact synapses with their cell processes and 
they are actively and specifically involved in synaptic signaling. They take up potassium 
ions and neurotransmitters like glutamate released by neurons and release gliotransmitters 
to modulate synaptic transmission [1]. These active functions in synaptic signaling led to 
the concept of the tripartite synapse, that is, the view that astrocytes processes are a third 
integral component of synapses beside the pre- and postsynaptic neuronal compartments 
[1]. Astrocytes also have important functions in development, as structural scaffold and 
in neuronal maturation [1]. Furthermore, neural stem cells (NSCs) in development (radial 
glia) and the adult brain show extraordinarily high similarity to astrocytes, and recent 
studies indicate that classical parenchymal astrocytes can regain NSC-like properties [2]. 
Therefore, NSCs might even be considered to be a part of a broad continuous spectrum of 
astrocyte-like cells [2].
For many of their diverse functions in normal brain development and homeostasis, astrocytes 
need to closely monitor and respond to changes in their environment. Therefore, it is not 
surprising that astrocytes also strongly respond to pathological conditions. This can result in 
the gain of novel functions, like immune cell-like functions, but also in the disruption of their 
normal homeostatic functions, adding an additional layer of complexity to astrocyte biology. 
Due to the important functions of astrocytes and their prominent alterations in pathologies, 
astrocytes are known or suspected to be involved in the pathogenesis of a large number of 
neurological conditions, from acute injury and inflammatory diseases to neurodegenerative 
and even psychiatric disorders [3, 4].
Astrocytes express a large set of receptors allowing them to detect a wide spectrum of 
changes in their environment, which activate various signaling pathways. Many of these 
receptors detect molecules occurring in pathological conditions, for example, pathogen-
derived molecules, molecules derived from damaged cells (pathogen-associated molecu-
lar patterns/Danger associated molecular patterns (PAMPs/DAMPs)), and cytokines [5, 6]. 
Signaling of most of these receptors converges on one major signaling pathway, the IKK/
NF-κB signaling pathway. This pathway is a master regulator of inflammation, and one of 
the main pathways controlling the pathophysiological responses of astrocytes, as will be 
discussed in detail in this chapter.
2. Astrogliosis: responses of astrocytes to pathological conditions
Most CNS pathologies, ranging from acute damage in traumatic brain injury (TBI) or CNS 
infections to inflammatory disorders like multiple sclerosis (MS), epilepsy and classical 
chronic neurodegenerative diseases like Alzheimer’s disease (AD) are associated with similar 
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characteristic histopathological alterations of astrocytes, which are generally referred to as 
astrogliosis [1]. Astrogliosis is usually associated with local inflammatory processes elicited 
by these pathological conditions. Similarly, microglia, the resident macrophages of the CNS, 
show characteristic alterations in these conditions, called microgliosis, which usually occur 
together with astrogliosis. [3, 7, 8].
A common feature of astrogliosis is astrocyte hypertrophy, along with an upregulation of 
proinflammatory mediators and intermediate filaments like the classical astrocyte and astro-
gliosis marker GFAP [1, 5, 6, 9]. Depending on the severity and type of insult, this hyper-
trophic response can also be accompanied by astrocyte proliferation and can result in the 
formation of dense glial scars [10].
The production of inflammatory mediators like cytokines (e.g. TNF, IL-1β) and chemokines 
(e.g. MCP1 (CCL2), RANTES (CCL5) and IP-10 (CXCL10)) by reactive astrocytes is crucial for 
the recruitment of peripheral immune cells into the CNS and their subsequent activation [3, 5]. 
This astrocyte-mediated immune cell recruitment is essential to fight infections and repair tissue 
damage, but exacerbated or chronic immune cell infiltration also drives autoimmune patholo-
gies like MS, and can aggravate other pathologies associated with neuroinflammation, like neu-
rodegenerative disorders [3, 11].
In response to pathological conditions, beside recruiting professional immune cells, astro-
cytes themselves contribute to inflammation and immune responses by producing a variety 
of acute phase response factors, like complement proteins (e.g. C1q, C3) or Lcn2 [12, 13]. 
While these factors can have important protective functions, for example, by inhibiting bacte-
rial growth in case of an infection, they can also promote synapse elimination and neuronal 
cell death [12, 13]. Interestingly, reactive astrocytes also upregulate MHC class II genes and 
have phagocytic capabilities [14, 15]. Therefore reactive astrocytes might act as professional 
antigen-presenting cells, similar to macrophages and dendritic cells [14, 15].
Overall, these inflammation-related and immune cell-like properties gained by reactive astro-
cytes suggest that astrocytes, beside microglia, are a second major component of the innate 
immune system of the brain.
The inflammatory functions of astrocytes are important for a fast and strong early response of 
the CNS to pathological conditions, which can be crucial to limit damage, for example, in infec-
tions or acute injury. This local response is particularly important in the CNS, because as an 
immune-privileged organ it has limited surveillance by peripheral immune cells. But inflamma-
tion increases cellular stress by various mechanisms, therefore chronic or exaggerated inflam-
matory astrocyte activation can have severe adverse effects resulting in neurotoxicity [16]. These 
early inflammatory responses of astrocytes are similar to the early responses of microglia and 
macrophages to pathological conditions, often described as proinflammatory M1 polarization 
[17]. Therefore, this type of astrocyte responses was recently described as A1 activation [16].
In addition to increased inflammatory stress, this type of astrocyte activation can also disrupt 
their normal homeostatic functions, like BBB maintenance, or the clearance of extracellular 
Signaling Pathways Regulating the Pathophysiological Responses of Astrocytes: A Focus on the…
http://dx.doi.org/10.5772/intechopen.72283
13
neurotransmitters (e.g. glutamate) and potassium ions released during synaptic activity 
[1, 18, 19]. Disruption of these astrocyte functions can cause edema formation and alters neu-
ronal excitation and network activity, which can result in behavioral changes, epileptic seizures 
and excitotoxic neurodegeneration [3, 18, 19].
Beside the described prominent proinflammatory phenotype, which in some conditions can 
have adverse consequences, reactive astrocytes also seem to occur in more “benign” states, 
which has been described as A2 activation, in analogy to a similar anti-inflammatory, pro-
regenerative state of microglia and macrophages (M2 polarization) [16, 17].
In chronic neurodegenerative or neuroinflammatory pathologies, A1 astrocyte activation 
seems to dominate, whereas after acute injury or ischemia, this A2 activation seems to deter-
mine the overall functional consequences of astrogliosis [16]. In these acute insults, reactive 
A2 astrocytes upregulate neurotrophic factors and can gain overall neuroprotective func-
tions [16].
After acute brain injury, for example, in models of cortical stab wound injury or spinal cord 
injury (SCI), but not in chronic neurodegenerative or neuroinflammatory pathologies, astro-
cytes also respond by proliferation and the formation of dense astroglial scars [10, 20, 21]. 
It is often assumed that this glial scar is required to restrict the spreading of tissue damage 
in the acute stage of the injury, but interferes with CNS regeneration on the long term, for 
example, by preventing axonal regrowth through the scar tissue. However, several studies 
indicate that also on the long term, the astrocytes of the glial scar rather promote repair 
and regeneration [10, 20]. Specifically, ablation of proliferating astrocytes has been shown 
to interfere with the repair of the BBB in cortical stab wound injury and SCI models, and 
prevented axonal regrowth after SCI stimulated by a conditioning lesion and neurotrophin 
application [20, 22, 23]. In addition, recent studies suggest that astrocytes not only protect 
the surviving of neurons in the damaged tissue, but might also reactivate a NSC-like poten-
tial, and might thereby contribute to the (very limited) generation of new neurons after 
injury [21, 24–26].
3. The IKK/NF-κB signaling pathway: a central signaling hub in 
inflammation, cell survival, proliferation and differentiation
The IKK/NF-κB pathway is a master regulator of inflammation, which is also implicated in a 
wide range of other biological processes, including cell death/survival, proliferation and dif-
ferentiation [27–29]. This signaling pathway integrates signals from a large number of differ-
ent receptors, converging in the activation of the IκB kinase (IKK) complex, the key activator 
of the NF-κB family of transcription factors in canonical NF-κB signaling [28]. In mammals, 
the NF-κB family includes the five members—RelA, RelB, c-Rel, p105/p50 and p100/p52, 
which form homo- and heterodimers [28]. In the basal state, these dimers are kept inactive in 
the cytoplasm by binding to proteins of the inhibitor of NF-κB (IκB) family [28].
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The IKK complex, consisting of the kinase subunits IKK1 and IKK2 (also called IKKα and IKKβ) 
and the regulatory subunit NEMO (IKKγ), can activate NF-κB dimers by phosphorylating IκB 
proteins through IKK2 as active kinase subunit [28]. This induces the poly-ubiquitination and 
subsequent proteasomal degradation of the IκB proteins, resulting in the release of the NF-κB 
dimers [28]. These dimers then can translocate to the nucleus, where they can activate or repress 
a large number of target genes [28].
Various inflammation-mediating receptors activate NF-κB through this canonical signaling 
pathway, including the TNF receptor TNFR1 and the IL-1β receptor as prototypical examples 
[28]. Upon activation, these receptors recruit K63-ubiquitin ligases like the cIAP proteins, and 
the linear ubiquitin assembly complex (LUBAC) [30, 31]. These ubiquitin ligases build K63- 
and linear (M1-) poly-ubiquitin chains on receptor-associated scaffolding proteins, which 
form the backbone for the assembly of large signaling complexes [30, 31]. The TAK1/TAB2/3 
and IKK kinase complexes then bind to these poly-ubiquitin chains, allowing the phosphory-
lation of IKK2 at two conserved serine residues by TAK1 and IKK2 itself [30, 31]. This dual 
phosphorylation of IKK2 is the key step in the activation of the IKK complex, which is then 
capable of phosphorylating IκB proteins [30, 31].
Beside TNFR1 and the IL-1β receptor, among the receptors activating this canonical NF-κB 
signaling pathway there are also many pattern recognition receptors (PRRs), like Toll-like 
receptors (TLRs) and NOD-like receptors (NLRs) [6, 28, 32]. These receptors are sensors 
of molecular danger signals, like conserved pathogen-derived molecules (pathogen-asso-
ciated molecular patterns, PAMPs) and molecules released by damaged cells (danger-
associated molecular patterns, DAMPs), which are driving the initiation of inflammatory 
responses [6, 28, 32].
Some other extracellular signals, like CD40L, LTβ, BAFF or RANKL, can activate an alterna-
tive NF-κB signaling pathway, by activation of IKK1 via the NF-κB inducing kinase (NIK). 
This induces the proteasomal processing of the NF-κB precursor subunit p100, resulting in 
the degradation of an inhibitory IκB domain of p100 [27]. This processing leaves the active 
subunit p52, which can translocate to the nucleus as a p52/p52 or RelB/p52 dimer [27].
In addition, several other stimuli, including neurotrophins and general cellular stress, like 
DNA damage and high levels of reactive oxygen species, can activate NF-κB signaling. In 
these cases, NF-κB activity is often regulated via atypical NF-κB signaling pathways, which 
involve various posttranslational modifications of IKK and NF-κB subunits [28, 33–35].
As diverse as the range of NF-κB activating stimuli are the target genes of the NF-κB transcrip-
tion factors. NF-κB signaling controls the expression of a large number of inflammatory cyto-
kines, chemokines, cell adhesion molecules, immunoreceptors and acute phase response genes 
[36]. As NF-κB signaling is activated by a wide range of inflammatory stimuli, and induces a 
large number of proinflammatory target genes, it can both initiate inflammatory responses 
and enhance them by positive feedback loops via NF-κB activating cytokines. These proper-
ties make the NF-κB signaling system a critical master regulator of inflammatory processes. In 
fact, IKK/NF-κB activation alone is sufficient to initiate and maintain inflammatory responses 
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in many tissues, which often phenotypically closely resemble classical autoimmune/inflamma-
tory diseases. This has been shown by us and others by conditional genetic activation of IKK/
NF-κB in pancreatic acinar or β-cells, hepatocytes, cardiomyocytes and airway or intestinal 
epithelial cells [37–43]. Vice versa, genetic inactivation of IKK/NF-κB signaling strongly sup-
presses inflammation in many mouse models of pathological conditions. This often amelio-
rates pathology, for example, in a model of cerebral ischemia with inactivated neuronal IKK/
NF-κB signaling [44], or in an MS model with inactivated IKK/NF-κB signaling in all neuroec-
todermal cells [45].
Among the large spectrum of NF-κB targets are also many genes controlling cell prolifera-
tion, differentiation and survival, like growth factors, cyclins and apoptosis regulators of the 
Bcl-2 and IAP families [29, 36]. Therefore NF-κB signaling represents a crucial link between 
inflammation and cancer [29, 36]. In addition, in the CNS, NF-κB signaling regulates neuronal 
differentiation and function, for example, dendrite formation and synaptogenesis, via various 
target genes like neurotrophins or IGF2 [34, 46–48].
In conclusion, the NF-κB signaling pathway is a central signaling hub integrating a large spec-
trum of signals to regulate a similar broad range of biological processes. One important func-
tion is the transduction of pathophysiological alarm signals, which is crucial for the cellular 
responses to these signals, in particular for inflammatory responses. Due to its diverse other bio-
logical functions, the NF-κB signaling pathway is a critical molecular link between inflamma-
tion and various physiological processes known to be dysregulated in inflammatory conditions.
4. Activation of the IKK/NF-κB pathway in astrocytes
Considering the responsiveness of astrocytes to pathological conditions and the central role 
of NF-κB in the transduction of such responses, it is not surprising that NF-κB signaling in 
astrocytes is activated in many pathological conditions and regulates many of these patho-
physiological responses.
Astrocytes express a large number of cytokine receptors including TNFR1 and IL-1RI; PRRs 
including TLRs (TLR2,3,5,9); NLRs including NOD2 and NLRP3 and RIG-1 like receptors 
(RLRs), which can activate NF-κB signaling in pathological conditions [5, 49, 50].
Accordingly, astrocytes activate NF-κB signaling in vitro after stimulation with ligands of 
these receptors, and in vivo in various neuropathological conditions associated with neuro- 
inflammation.
For example, in vitro, stimulation of primary mouse astrocytes with TNFα or IL-1β induces 
nuclear accumulation of RelA indicating NF-κB activation (e.g. [45]). In vivo, astroglial NF-κB 
activation was described, for example, in MS [51], traumatic brain injury (TBI) [52], in chronic 
neurodegenerative pathologies such as ALS [53] and Huntington’s disease (HD) [54], but 
remarkably also in a post-mortem study in autism spectrum disorders [55].
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5. Functions of astroglial IKK/NF-κB signaling: a central regulator of 
the pathophysiological responses of astrocytes
To investigate the specific functions of NF-κB signaling in astrocytes in vivo, we and other 
groups have developed conditional transgenic mouse models allowing the genetic activation 
or inactivation of NF-κB signaling specifically in astrocytes and closely related cell types.
One much-studied mouse model was developed by the group of John R. Bethea, the GFAP-
IκBα-dn transgenic mouse line [56]. In this mouse model, astroglial NF-κB signaling is 
strongly inhibited by overexpression of a dominant-negative, non-degradable mutant of the 
NF-κB inhibitor IκBα [56]. The transgene expression is driven by the GFAP promoter, which 
restricts its expression to astrocytes and closely related cell types [56].
Vice versa, to genetically activate IKK/NF-κB signaling, we generated a mouse model allow-
ing the inducible overexpression of a constitutively active mutant of IKK2 specifically in 
astrocytes (GFAP.tTA/tetO.IKK2-CA) [57]. Using a so-called Tet-off conditional expression 
system, the expression of this transgene is driven by the GFAP promoter and can be revers-
ibly repressed by the administration of doxycycline, allowing both constitutive and time-
controlled transient activation of astroglial IKK/NF-κB signaling [57, 58].
Other strategies to manipulate astroglial IKK/NF-κB signaling include the Cre-mediated dele-
tion of components of the IKK complex to block NF-κB activation [45], or deletion of IκBα to 
enhance astroglial NF-κB signaling [59].
A number of studies using these or similar approaches have revealed important functions of 
astroglial NF-κB signaling in normal CNS development and homeostasis, as well as critical 
roles in the regulation of astroglial responses to pathological conditions.
5.1. Astroglial IKK/NF-κB signaling is a central regulator of neuroinflammation
In line with the key role of IKK/NF-κB signaling in the regulation of inflammation in other cell 
types, and the important role of astrocytes in neuroinflammation, a number of studies have 
established that astroglial IKK/NF-κB activation is a critical step in the initiation and propaga-
tion of neuroinflammatory processes.
In the initial description of the GFAP-IκBα-dn model, it was shown that IKK/NF-κB inhibition 
in astrocytes in SCI reduced the expression of the proinflammatory chemokines CCL2 (MCP-1) 
and CXCL10 (IP-10), which are important regulators of immune cell recruitment [56]. This 
study also showed that the upregulation of the astrogliosis-promoting cytokine TGFβ2 after 
SCI is mediated by astroglial NF-κB signaling [56].
A subsequent study on the role of NF-κB signaling in experimental autoimmune encepha-
litis (EAE), a model of MS, showed that inhibition of NF-κB signaling in all neuroectoder-
mal cells (Nes-Cre/NEMO fl/fl and Nes-Cre/IKK2 fl/fl) prominently reduced the expression 
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of a large spectrum of inflammatory mediators in this pathology [45]. This study indicated 
that inhibition of astroglial NF-κB signaling was predominantly responsible for this ame-
lioration of neuroinflammation, which was confirmed later by astrocyte-specific NF-κB 
inhibition using the GFAP-IκBα-dn model [60]. GFAP-IκBα-dn transgenic mice in this 
study showed a similar reduction of the expression of inflammatory mediators after EAE 
[60]. These mediators included various chemokines and cell adhesion molecules involved 
in the recruitment of peripheral immune cells, and the major proinflammatory cytokines 
TNF, IL-1β and IFN-γ, as well as inflammatory effector genes like complement factors 
[45, 60].
These findings suggest that astroglial IKK/NF-κB signaling is important for the recruitment 
and activation of immune cells in neuroinflammatory conditions. Indeed, in both mentioned 
models, a reduced infiltration of immune cells after EAE induction was found in mice with 
inhibited astroglial IKK/NF-κB signaling [45, 61], although originally also an increase of (reg-
ulatory) T cell infiltration was described for the GFAP-IκBα-dn model [60].
Similar to the situation in EAE and SCI, inhibition of astroglial NF-κB signaling by GFAP-
IκBα-dn also resulted in a reduced induction of multiple proinflammatory factors in mod-
els of retinal ischemia-reperfusion injury [62] and optic neuritis [63]. While this reduced 
microgliosis and astrogliosis in ischemic injury [62], infiltration of peripheral immune 
cells in optic neuritis was not obviously altered, although this was not quantified in this 
study [63].
Overall, these studies demonstrate that astroglial NF-κB signaling mediates the coordinated 
induction of various inflammatory mediators in various neuropathologies. However, the con-
sequences of this proinflammatory signaling for local glial reactivity and the infiltration of 
peripheral immune cells depend on the specific pathological context. Whether these context-
dependent effects in different pathologies are due to different levels of NF-κB activation, or 
whether additional signaling pathways are required for astrocytes to modulate neuroinflam-
mation, was not investigated by these studies. Also, they could not address the question, 
whether astroglial NF-κB activation can only modulate neuroinflammation induced by other 
processes in these specific pathologies, or whether it is actually a driving force of neuroin-
flammation, which is sufficient to initiate neuroinflammation.
To address these questions, we generated the GFAP.tTA/tetO.IKK2-CA model, which allows 
astroglial NF-κB activation in normal physiological conditions, that is, in the absence of an 
external pathogenic trigger that could induce neuroinflammation [57]. Remarkably, both in 
the developing, early postnatal brain and in the adult brain, the selective activation of astro-
glial NF-κB in this model was sufficient to initiate and maintain a prominent global neuro-
inflammatory response [57, 58, 64]. This inflammatory response was characterized by strong 
astrogliosis and microgliosis, as well as a prominent infiltration of innate immune cells, and, 
in adult animals, also T cells [57, 58, 64]. On a molecular level, in particular the chemokines 
CCL2(MCP-1), CCL5(Rantes) and CXCL10(IP-10), the cell adhesion molecule Madcam1, 
the MHC class II protein CD74 and some acute phase effector genes (Lcn2, C3) were highly 
upregulated by astroglial IKK/NF-κB activation [57, 58]. These inflammatory mediators and 
Astrocyte - Physiology and Pathology18
effectors were upregulated both in brain tissue and in primary astrocytes, suggesting that 
they are direct targets of IKK/NF-κB signaling in astrocytes [57, 58]. In contrast, TNF and 
IL-1β were induced in adult cerebellar tissue of these animals [58], but not in primary astro-
cytes [57]. This indicates that these major proinflammatory cytokines are not direct NF-κB 
targets in astrocytes, but that they are produced by other cell types as an indirect consequence 
of astroglial IKK/NF-κB activation.
In conclusion, these studies show that astroglial IKK/NF-κB signaling is a key regulator of 
inflammatory responses in the CNS, whose activation is required and can be sufficient to 
initiate and maintain neuroinflammation. Specifically, astroglial IKK/NF-κB activation alone 
is sufficient to induce the infiltration of peripheral immune cells into the brain, probably via 
the strong induction of chemokines. However, in specific disease contexts this can also occur 
independently of astroglial IKK/NF-κB signaling, and other cell types or signaling pathways 
are likely required for the production of major cytokines to activate these immune cells. 
Furthermore, astroglial IKK/NF-κB activation can trigger astrogliosis and induce a number 
of acute phase response factors, which might be important for the rapid response of the CNS 
to acute pathological insults, to limit potential further damage, for example, in an infection 
or injury.
5.2. Astroglial IKK/NF-κB activation can interfere with postnatal brain development
Astrocytes and related cell types, like radial glia, have important functions in CNS develop-
ment [1], and neuroinflammatory conditions like brain infections, which are associated with 
NF-κB activation in astrocytes, are known to be major risk factors for neurodevelopmental 
disorders [65, 66]. This suggests that NF-κB-mediated astroglial responses during CNS devel-
opment might contribute to the pathogenesis of such inflammation-associated neurodevelop-
mental disorders.
Indeed, in line with this hypothesis, we found that constitutive activation of astroglial IKK/
NF-κB signaling during early postnatal brain development in the GFAP.tTA/tetO.IKK2-CA 
model resulted in lethality due to neuroinflammation-associated hydrocephalus formation 
[57]. Hydrocephalus is a known complication of neuroinflammatory insults, in particular 
during brain development [57]. In the GFAP.tTA/tetO.IKK2-CA model, hydrocephalus for-
mation was caused by impaired differentiation of the ependymal cells lining the cerebral 
ventricles, which failed to develop motile cilia [57]. These cilia are required to facilitate 
the flow of the cerebrospinal fluid through the cerebroventricular system, and defects of 
these cilia can cause hydrocephalus also in other mouse models [57]. Ependymal cells are 
closely related to astrocytes and develop postnatally from radial glia, which are common 
progenitors of both astrocytes and ependymal cells [2]. Thus, at least some ependymal cells 
expressed the IKK2-CA transgene [57]. Therefore, it is not clear whether this defect is cell-
intrinsic, or whether non-cell-autonomous effects of astrocyte-mediated neuroinflamma-
tion contribute to this defect [57]. Beyond hydrocephalus formation, astroglial IKK/NF-κB 
activation in the GFAP.tTA/tetO.IKK2-CA model resulted in additional defects in late devel-
oping brain regions, specifically in a disorganization of the hippocampus, most prominently 
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in the dentate gyrus, and a delayed maturation of the cerebellum [57]. These defects might 
be caused by an impaired migration of neural progenitors, as this migration is guided by 
chemokine gradients, which are likely disturbed by the massive NF-κB-mediated upregu-
lation of chemokines by astrocytes, and the overall inflammatory environment [57].
These findings demonstrate that astroglial IKK/NF-κB activation can interfere with normal 
brain development, providing a potential molecular link between neuroinflammation and 
neurodevelopmental disorders. On the other hand, inhibition of IKK/NF-κB signaling in 
astrocytes does not cause obvious defects of brain development and homeostasis [45, 56]. 
Therefore, it will be interesting to study to what extent inhibition of astroglial IKK/NF-κB 
signaling can ameliorate inflammation-associated neurodevelopmental defects.
5.3. Roles of astroglial IKK/NF-κB signaling in normal adult brain homeostasis and 
function
Mice with IKK/NF-κB inhibition in astrocytes do not show obvious phenotypes in normal 
physiological conditions [45, 56], demonstrating that astroglial NF-κB signaling is not broadly 
required for normal brain development, homeostasis and function. However, two studies 
reported subtle behavioral phenotypes of mice with reduced basal astroglial IKK/NF-κB 
signaling, specifically a sex-specific impairment in learning and memory in female GFAP-
IκBα-dn mice [67], and reduced food intake in mice with Cre-mediated astroglial IKK2 inac-
tivation (GFAP-Cre/IKK2 fl/fl) [68].
On the other hand, as described in Section 5.1, activation of astroglial IKK/NF-κB signaling 
in normal physiological conditions in the adult brain in the GFAP.tTA/tetO.IKK2-CA model 
induces prominent global neuroinflammation [58, 64]. This indicates that activation of IKK/
NF-κB signaling in astrocytes might have more severe consequences for brain homeostasis 
and function than its inhibition. Interestingly however, this prominent global neuroinflam-
matory phenotype had obvious consequences for brain homeostasis only in one specific brain 
region, the cerebellum [58]. In the cerebellum, with some delay massive neurodegeneration 
was observed, which predominantly affected Purkinje cells, the output neurons of the cerebel-
lum and resulted in severe motor impairment [58]. This was found to be due to the dysfunc-
tion of the Bergmann glia, a specific population of astrocytes with radial glia-like morphology, 
which is essential for the function and survival of the Purkinje neurons [58]. IKK2 activa-
tion in Bergmann glia resulted in prominent astrogliosis-like alterations, including prominent 
upregulation of GFAP and morphological alterations disrupting their specialized morphology 
[58]. These alterations were shown to represent an irreversible “point of no return” resulting 
in inevitable Purkinje cell degeneration [58]. Of note, this phenotype resembles alterations 
found in inflammatory cerebellar neurodegenerative disorders, for example, in paraneoplas-
tic cerebellar degeneration, which are also characterized by prominent selective Purkinje cell 
degeneration [58]. Therefore, these findings suggest a mechanism how cerebellar neuroin-
flammation caused by various insults might result in the common pathology of Purkinje cell 
degeneration: Inflammation-induced IKK/NF-κB activation in Bergmann glia would cause 
irreversible Bergmann glia dysfunction, which consequentially would drive Purkinje cell 
degeneration [58].
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Interestingly, it was also found that astroglial IKK/NF-κB activation in the GFAP.tTA/tetO.
IKK2-CA model resulted in the downregulation of the glutamate transporters EAAT1 (GLAST) 
and EAAT2 (GLT-1) in the cerebellum and the medulla oblongata [58]. Downregulation of 
these transporters is found in many neurological disorders, including cerebellar neurodegen-
erative disorders, and is believed to contribute to the pathogenesis of these disorders [18, 69]. 
By impairing the uptake of the excitatory neurotransmitter glutamate by astrocytes, down-
regulation of these transporters can result in neuronal hyperexcitation and excitotoxic neuro-
degeneration [18, 69].
Another recent study found that astroglial IKK/NF-κB activation also impairs the astro-
glial uptake of the neurotransmitter GABA, at least in the hypothalamus, which resulted in 
increased activity of specific neurons in hypothalamic nuclei [68]. In this model, a consti-
tutively active IKK2 allele was activated by GFAP-Cre-mediated recombination (GFAP-Cre/
Rosa26-LSL-IKK2CA) [68]. This resulted in more moderate astroglial IKK/NF-κB activa-
tion, which was not sufficient to induce neuroinflammation in heterozygous mice [68]. In 
this model, astroglial IKK/NF-κB activation led to mild astrogliosis-like changes, specifically 
increased astrocyte numbers and altered morphology (shortened processes) [68]. These alter-
ations resulted in changes in the systemic metabolism, which is controlled by the hypothala-
mus, specifically in a metabolic syndrome-like phenotype with insulin resistance, increased 
blood pressure and increased fat deposition [68].
Given the important functions of astrocytes in neuronal metabolism and signaling, and 
their prominent alterations in pathological conditions, it is likely that astroglial IKK/NF-κB 
activation also causes additional more subtle alterations in neuronal communication in the 
CNS. Indeed, we have found a moderate reduction of striatal dopamine levels in the GFAP.
tTA/tetO.IKK2-CA model [64]. However, more research is needed to examine the functions of 
astroglial IKK/NF-κB in the modulation of neurotransmitter signaling.
Another mechanism beside the uptake of neurotransmitters and release of gliotransmitters, 
by which astrocytes modulate neuronal communication, is the regulation of synapse forma-
tion, maturation and elimination. On a molecular level, complement proteins, including C3, 
which is highly induced by astrocytes upon NF-κB activation, contribute to the elimination of 
synapses [70]. Indeed, it has recently been demonstrated, that astroglial NF-κB activation by 
GFAP-Cre-mediated IκBα deletion promotes synapse elimination and alters neuronal signal-
ing via C3 induction [70].
5.4. Roles of astroglial IKK/NF-κB signaling in models of specific pathological 
conditions
Astrogliosis and neuroinflammatory processes are occurring in most neurological disorders, 
most prominently in autoimmune/inflammatory disorders and acute injury. Often these pro-
cesses contribute to the pathogenesis of these disorders, but depending on the conditions 
they can also have protective roles. Astroglial IKK/NF-κB signaling is a key regulator of these 
pathophysiological responses, therefore a number of studies have addressed the role of astro-
glial IKK/NF-κB signaling in specific CNS disease and injury models.
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The first neuropathological condition, in which the role of astroglial NF-κB signaling was 
studied using the GFAP-IκBα-dn model, was SCI, a condition in which inflammatory pro-
cesses are believed to prominently contribute to pathogenesis [56, 71]. In line with the 
idea that astroglial NF-κB signaling promotes neuroinflammation and that this aggravates 
pathogenesis of SCI, functional recovery was improved in mice with inhibited astroglial 
NF-κB signaling [56]. Histologically, microgliosis and astrogliosis were less pronounced in 
the absence of astroglial NF-κB signaling after SCI [71]. This was associated with improved 
white matter preservation, probably due to reduced secondary inflammatory white mat-
ter damage [56], which also improved axonal integrity [71]. Also, a reduced intra-lesional 
deposition of chondroitin sulfate proteoglycans (CSPGs) was observed [56]. CSPGs are 
important components of the glial scar, which interfere with regenerative axonal out-
growth [56]. In this model of contusive SCI, even some degree of axonal sprouting across 
the lesion was observed upon inhibition of astroglial NF-κB signaling, but not in wildtype 
animals [71]. This indicates that NF-κB-mediated scar formation contributes to the inabil-
ity of the CNS to regenerate lost axons. However, this regenerative response was not able 
to bridge the lesion in a complete spinal cord transection, showing that astroglial NF-κB 
inhibition is not sufficient to allow axonal regeneration [71]. In conclusion, these stud-
ies show that astroglial NF-κB signaling might contribute to the pathogenesis of SCI by 
aggravating inflammatory secondary tissue damage and by interfering with regenerative 
processes.
Another well studied neurological disorder with an obviously strong inflammatory patho-
genic component is MS, the most common autoimmune disease of the CNS. A number of 
studies have therefore investigated whether astroglial NF-κB signaling contributes to patho-
genesis of demyelination in this disease [45, 60, 61, 63, 72, 73].
In an early study indicating that indeed astroglial NF-κB signaling might contribute to MS 
pathogenesis, the core components of the IKK complex were inactivated in neuroectodermal 
cells (neurons, astrocytes and oligodendrocytes) in a mouse model using nestin-promoter 
driven Cre expression (Nes-Cre x IKK1 fl/fl or IKK2 fl/fl or NEMO fl/fl) [45]. After induction 
of EAE, mice with conditional IKK2 and NEMO inactivation, but not with IKK1 inactiva-
tion, displayed prominently reduced neurological deficits [45]. This indicates that canoni-
cal, but not non-canonical NF-κB signaling in astrocytes, oligodendrocytes and neurons, 
contributes to EAE pathogenesis [45]. These reduced neurological deficits were accompa-
nied by reduced demyelination and immune cell infiltration, and a reduced expression of 
proinflammatory genes in primary astrocytes [45]. Because microglia and astrocytes are the 
main cell types in the CNS parenchyma that regulate inflammatory processes, and microg-
lia are not targeted by the Nes-Cre-driven ablation approach, the authors concluded that 
reduced proinflammatory signaling by NF-κB inhibition in astrocytes is likely responsible 
for the amelioration of the phenotype [45]. This hypothesis was confirmed by astrocyte-spe-
cific NF-κB inhibition in EAE in the GFAP-IκBα-dn model [60, 61]. Astrocyte-specific NF-κB 
inhibition in this model also reduced neurological deficits after EAE induction, along with 
a reduced expression of inflammatory mediators, and led to improved remyelination and 
neuronal survival at chronic stages [60, 61]. Vice versa, GFAP-Cre-mediated inactivation 
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of A20, a negative feedback regulator of NF-κB signaling, in astrocytes, increased expres-
sion of proinflammatory NF-κB target genes and inflammatory infiltration after EAE, which 
resulted in aggravated neurological deficits and demyelination [72]. Interestingly, the 
observed myelin preservation after inhibition of astrocyte-specific NF-κB signaling is not 
restricted to EAE, which is driven by an autoimmune attack, that is, a very strong inflam-
matory insult. Increased myelin preservation was also observed in a model of cuprizone-
induced toxic demyelination, where inflammatory events are not the primary cause but 
rather a co-pathogenic consequence of the myelin damage [73]. This indicates that NF-κB-
mediated astroglial responses contribute to the pathogenesis of demyelination not only by 
inflammatory signaling, for example, by promoting the recruitment of peripheral immune 
cells, but that astrocytes gain additional pathogenic properties after NF-κB activation. In 
line with this idea, demyelination in the optic nerve, one of the earliest symptoms of MS, is 
reduced in EAE in the GFAP-IκBα-dn model even without any obvious differences in local 
immune cell infiltration [63]. It was proposed that astroglial NF-κB signaling in the latter 
paradigm contributes to myelin damage by increasing oxidative stress, as it induces the 
NAD(P)H oxidase subunits Cybb/NOX2 and Ncf1 [63].
Overall, these studies provide clear evidence that activation of NF-κB-mediated inflamma-
tory responses of astrocytes aggravate demyelination and associated neurological defects in 
different animal models, indicating that these NF-κB-mediated astrocytic responses likely 
contribute to the pathogenesis of MS and other demyelinating disorders.
For other neurological disorders, the functions of astroglial NF-κB signaling are less well 
studied.
In a model of ischemic retinal injury, astroglial NF-κB inhibition in GFAP-IκBα-dn mice 
was shown to be neuroprotective, likely by suppressing the induction of Nos2 (iNos) and 
NADPH-oxidase genes after ischemia [62, 74]. This resulted in a reduction of oxidative stress, 
a crucial pathogenic factor in ischemia, at least in vitro [62, 74]. In contrast, an earlier study 
using a model with a different astrocyte-specific dominant-negative IκBα transgene did not 
find any consequences of astroglial NF-κB inhibition for the pathogenesis of cerebral isch-
emia [75].
A reduction of the expression of the oxidative stress promoting enzyme iNos by astroglial 
NF-κB inhibition in GFAP-IκBα-dn mice was also found in a model of hepatic encephalopa-
thy [76]. In this model, astroglial NF-κB inhibition had a protective effect due to a prominent 
reduction of astrocyte swelling and edema formation [76].
These findings, as the described similar findings in EAE/optic neuritis [63], indicate that astro-
glial NF-κB signaling increases oxidative stress, which might contribute to the pathogenesis 
of a range of neuroinflammation-associated neuropathological conditions.
Classical chronic neurodegenerative disorders like AD, PD or ALS are also associated with 
neuroinflammatory processes, which are believed to contribute to the pathogenesis of these 
diseases. However, only few studies so far have addressed the role of astroglial NF-κB signal-
ing in models of chronic neurodegeneration.
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One study found that Aβ can activate NF-κB in astrocytes, resulting in C3 induction [70]. 
Further, this study showed that in AD C3 levels are elevated, and that inhibition of the C3 
receptor C3aR can revert memory deficits in a mouse model of AD [70]. This suggests that 
astroglial NF-κB activation via C3 induction might contribute to AD pathogenesis. However, 
a direct link of astroglial NF-κB activation and disease pathogenesis in AD has yet to be 
demonstrated.
To study the role of astroglial NF-κB signaling in PD, we have analyzed the consequences of 
enhanced NF-κB activation in astrocytes in GFAP.tTA/tetO.IKK2-CA mice for neurodegen-
eration in the MPTP model of PD [64]. In this paradigm, astroglial NF-κB activation did not 
affect the degeneration of dopaminergic neurons in the substantia nigra, despite inducing 
prominent neuroinflammation in this brain region [64]. This argues against a prominent role 
of astroglial NF-κB signaling in PD pathogenesis. However, the mechanism of degeneration 
in this toxin-induced dopaminergic neurodegeneration model differs from the mechanism of 
degeneration in PD, therefore studies in other models of PD should be undertaken to further 
elucidate the role of astroglial NF-κB signaling in PD.
Finally, one study inhibited astroglial NF-κB signaling in a mouse model of ALS, using 
another independent GFAP-IκBα-dn transgenic mouse line [77]. Rather unexpectedly, despite 
the well documented contribution of astrocytes to ALS pathogenesis and a delayed onset of 
astrogliosis and microgliosis in this model, no alterations in disease onset or progression were 
found in this model [77]. This argues against a prominent contribution of astroglial NF-κB 
signaling to astrocyte dysfunction and neurodegeneration in ALS.
In conclusion, although astrocytes have crucial functions in neuroinflammation and neuro-
nal homeostasis, and neuroinflammation and astrocyte dysfunction are widely accepted as 
pathogenic mechanisms in chronic neurodegeneration, direct evidence for the contribution 
of astroglial NF-κB signaling to the pathogenesis of these disorders is scarce. Given the huge 
socioeconomic impact of these disorders, and the prominent role of astroglial NF-κB signal-
ing on the pathogenesis of other neurological disorders, further studies should address the 
role of astroglial NF-κB signaling in chronic neurodegeneration in more detail.
6. Other signaling pathways regulating pathophysiological 
responses of astrocytes: an overview
Although we have focused here on the role of NF-κB signaling in the regulation of patho-
physiological responses of astrocytes, several other signaling pathways have been implicated 
in these responses. Interestingly, many pathways involved in astrocyte reactivity are also 
required for astrocyte differentiation in development. Activation of these pathways in path-
ological conditions seems to promote a partial de-differentiation of astrocytes, resembling 
more immature stages of astrocyte differentiation with increased proliferative and lineage 
potential.
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One of these key developmental pathways contributing to astrocyte reactivity is the JAK/
STAT3 pathway, which is activated by cytokines of the IL-6 family, like IL-6, LIF and CNTF 
[78, 79]. This pathway is closely interconnected with the NF-κB pathway, as, for example, IL-6 
is induced in many inflammatory conditions, also by NF-κB activation in astrocytes [58]. Vice 
versa, JAK/STAT3 signaling induces target genes that are also induced by NF-κB signaling, 
like CXCL10 and LCN2 [78]. STAT3 activation in the context of pathological conditions was 
shown be a crucial driver of astrocyte hypertrophy and GFAP induction, two major hallmarks 
of astrogliosis [78]. Indeed, STAT3 directly regulates GFAP expression, in cooperation with 
SMAD transcription factors, which are activated by BMP and TGFβ signaling, another signal-
ing system implicated in astrogliosis [80].
Interestingly, while both NF-κB and STAT3 signaling promote astroglial scar formation in 
SCI, STAT3 regulated aspects of astroglial scar formation seem to promote repair and regen-
eration [20], whereas NF-κB regulated aspects rather interfere with repair processes [56, 71]. 
This indicates that different types of astroglial scars exist, which are regulated by different 
molecular mechanisms and which can influence regeneration in different ways. Therefore, 
future studies should further investigate these mechanisms, as this might open up new strate-
gies to promote regeneration after CNS damage, by converting astroglial scars to more pro-
regenerative states.
STAT3 signaling also contributes to the proliferative response of astrocytes observed after 
acute injury [78], a response which is also regulated by Sonic hedgehog (SHH) signaling [21]. 
Interestingly, this proliferative response seems to be directly linked to the acquisition of NSC-
like properties of astrocytes after injury, which similar to NSCs and immature astrocytes, can 
form multipotent neurospheres in vitro [21, 81]. This indicates that astrocytes after injury can 
partially de-differentiate, and can regain increased lineage plasticity, including the poten-
tial to generate new neurons. Indeed, recent studies have demonstrated that at least in the 
striatum, some astrocytes can generate neurons in vivo after cell cycle re-entry in response to 
ischemic or excitotoxic injury [25, 26]. In ischemic injury, this reactivation of proliferation and 
subsequent neurogenesis was associated with reduced Notch signaling [25], another pathway 
which is required for astrocyte differentiation and maturation, and which is also controlling 
NSC quiescence [82, 83].
This study further showed that genetic activation of Notch signaling can suppress this pro-
liferative and neurogenic response in ischemia [25]. Vice versa, inhibition of Notch signaling 
in astrocytes by conditional RBPJ deletion is sufficient to elicit a neurogenic response in some 
striatal astrocytes [25]. These results indicate that Notch signaling is crucial to maintain the 
mature, quiescent state of astrocytes, and that downregulation Notch signaling promotes a 
de-differentiation response of astrocytes in pathological conditions.
It will be important to further dissect the mechanisms governing these neurogenic de-differ-
entiation responses of astrocytes, which might open up new strategies for regenerative medi-
cine. This could allow enhancing endogenous neuronal replacement in neurodegenerative 
conditions and improving the efficiency of neuronal reprogramming of astrocytes.
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7. Conclusions and future directions
As we have described in this chapter, astrocytes are functionally diverse and plastic cells that 
are highly responsive to changes in the CNS microenvironment.
In most CNS pathologies, including acute injuries, autoimmune/inflammatory disorders like 
multiple sclerosis, and chronic neurodegenerative diseases like Alzheimer’s disease, astro-
cytes show prominent pathophysiological responses, often rather superficially described 
with the unifying terms astrogliosis or astrocyte reactivity. These responses share common 
features, but include also many distinct aspects in different CNS pathologies, and can have 
important protective or pathogenic consequences in these pathologies.
Therefore, understanding the precise mechanisms as how these responses are controlled and 
how they influence CNS development, homeostasis and pathology, is highly relevant for 
translational and clinical neuroscience.
A large spectrum of extracellular signals activating several intracellular signaling pathways 
regulates the pathophysiological responses of astrocytes. One central signaling hub integrat-
ing many of these extracellular signals is the IKK/NF-κB signaling pathway. A number of 
studies summarized here have established that the IKK/NF-κB pathway in astrocytes is a key 
regulator of neuroinflammatory responses. These studies also demonstrated that astroglial 
IKK/NF-κB activation interferes with normal CNS development and homeostasis and contrib-
utes to the pathogenesis of various CNS disorders in mouse models.
These findings have important implications for the development of new strategies for the 
treatment of CNS disorders. Although pharmacological targeting of the IKK/NF-κB pathway 
has proven to be difficult due to its broad spectrum of functions, it might be an option for 
some very specific conditions, where a transient inhibition of a particularly strong inflamma-
tory response might be beneficial, for example, in acute stages of autoimmune disorders or 
injury. In addition, the further investigation of the effector pathways of IKK/NF-κB signal-
ing in astrocytes will hopefully identify specific aspects of this broad response that can be 
targeted with more selective approaches. Such approaches could include, for example, the 
inhibition of specific chemokines or the complement system, the prevention of the morpho-
logical changes of astrocytes that might cause disruption of the blood-brain-barrier or neu-
ronal support functions, or the restoration of neurotransmitter uptake by astrocytes. Another 
important, unsolved question is, in which conditions astroglial NF-κB activation is actually 
beneficial. In most conditions investigated so far, astroglial NF-κB activation seems to have 
detrimental effects, but as this response is evolutionary conserved, it should have beneficial 
effects in some circumstances. One could speculate that acute CNS infections might require 
astroglial NF-κB activation to allow a rapid and strong response to stop spreading of the 
pathogens and to allow their efficient clearance. However, this has not been experimentally 
demonstrated yet.
As only shortly summarized here, also other signaling pathways have important functions in the 
regulation of astroglial responses to pathological insults, which, except for JAK/STAT signaling, 
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have received only relatively limited attention so far. The functions of these pathways in astro-
cytes should be investigated in more detail in future studies, and the functional interaction of 
these pathways with each other has to be elucidated. Manipulation of the balance of these path-
ways might allow to improve regenerative responses of astrocytes, as indicated, for example, 
by the detrimental versus beneficial roles of NF-κB and STAT3 signaling in astroglial scars for 
regeneration in spinal cord injury models.
Finally, the investigation of the mechanisms which regulate the only recently recognized neu-
rogenic responses of astrocytes, offers an exciting perspective for regenerative medicine. It 
might uncover approaches to stimulate endogenous replacement of lost neurons, which is 
an important mechanism of CNS repair in lower vertebrates, but has been largely lost in 
mammals.
Author details
Michael Lattke1* and Thomas Wirth2
*Address all correspondence to: michael.lattke@crick.ac.uk
1 Neural Stem Cell Biology Lab, The Francis Crick Institute, London, UK
2 Institute of Physiological Chemistry, University of Ulm, Ulm, Germany
References
[1] Sofroniew MV, Vinters HV. Astrocytes: Biology and pathology. Acta Neuropathologica. 
2010;119(1):7-35
[2] Gotz M et al. Reactive astrocytes as neural stem or progenitor cells: In vivo lineage, 
in vitro potential, and genome-wide expression analysis. Glia. 2015;63(8):1452-1468
[3] Sofroniew MV. Astrocyte barriers to neurotoxic inflammation. Nature Reviews. 
Neuroscience. 2015;16(5):249-263
[4] Allaman I, Belanger M, Magistretti PJ. Astrocyte-neuron metabolic relationships: For 
better and for worse. Trends in Neurosciences. 2011;34(2):76-87
[5] Farina C, Aloisi F, Meinl E. Astrocytes are active players in cerebral innate immunity. 
Trends in Immunology. 2007;28(3):138-145
[6] Colombo E, Farina C. Astrocytes: Key regulators of neuroinflammation. Trends in 
Immunology. 2016;37(9):608-620
[7] Ransohoff RM, Perry VH. Microglial physiology: Unique stimuli, specialized responses. 
Annual Review of Immunology. 2009;27:119-145
Signaling Pathways Regulating the Pathophysiological Responses of Astrocytes: A Focus on the…
http://dx.doi.org/10.5772/intechopen.72283
27
[8] Ransohoff RM, Brown MA. Innate immunity in the central nervous system. The Journal 
of Clinical Investigation. 2012;122(4):1164-1171
[9] Liddelow SA, Barres BA. Reactive astrocytes: Production, function, and therapeutic 
potential. Immunity. 2017;46(6):957-967
[10] Pekny M, Pekna M. Astrocyte reactivity and reactive astrogliosis: Costs and benefits. 
Physiological Reviews. 2014;94(4):1077-1098
[11] Frank-Cannon TC et al. Does neuroinflammation fan the flame in neurodegenerative 
diseases? Molecular Neurodegeneration. 2009;4:47
[12] Jha MK et al. Diverse functional roles of lipocalin-2 in the central nervous system. 
Neuroscience and Biobehavioral Reviews. 2015;49:135-156
[13] Stephan AH, Barres BA, Stevens B. The complement system: An unexpected role in 
synaptic pruning during development and disease. Annual Review of Neuroscience. 
2012;35:369-389
[14] Dong Y, Benveniste EN. Immune function of astrocytes. Glia. 2001;36(2):180-190
[15] Carpentier PA et al. Differential activation of astrocytes by innate and adaptive immune 
stimuli. Glia. 2005;49(3):360-374
[16] Liddelow SA et al. Neurotoxic reactive astrocytes are induced by activated microglia. 
Nature. 2017;541(7638):481-487
[17] Prinz M, Priller J. Microglia and brain macrophages in the molecular age: From origin to 
neuropsychiatric disease. Nature Reviews. Neuroscience. 2014;15(5):300-312
[18] Tilleux S, Hermans E. Neuroinflammation and regulation of glial glutamate uptake in 
neurological disorders. Journal of Neuroscience Research. 2007;85(10):2059-2070
[19] Jukkola P, Gu C. Regulation of neurovascular coupling in autoimmunity to water and 
ion channels. Autoimmunity Reviews. 2015;14(3):258-267
[20] Anderson MA et al. Astrocyte scar formation aids central nervous system axon regen-
eration. Nature. 2016;532(7598):195-200
[21] Sirko S et al. Reactive glia in the injured brain acquire stem cell properties in response to 
sonic hedgehog. [corrected]. Cell Stem Cell. 2013;12(4):426-439
[22] Bush TG et al. Leukocyte infiltration, neuronal degeneration, and neurite outgrowth 
after ablation of scar-forming, reactive astrocytes in adult transgenic mice. Neuron. 
1999;23(2):297-308
[23] Faulkner JR et al. Reactive astrocytes protect tissue and preserve function after spinal 
cord injury. The Journal of Neuroscience. 2004;24(9):2143-2155
Astrocyte - Physiology and Pathology28
[24] Buffo A et al. Origin and progeny of reactive gliosis: A source of multipotent cells in the 
injured brain. Proceedings of the National Academy of Sciences of the United States of 
America. 2008;105(9):3581-3586
[25] Magnusson JP et al. A latent neurogenic program in astrocytes regulated by Notch sig-
naling in the mouse. Science. 2014;346(6206):237-241
[26] Nato G et al. Striatal astrocytes produce neuroblasts in an excitotoxic model of 
Huntington's disease. Development. 2015;142(5):840-845
[27] Zhang Q, Lenardo MJ, Baltimore D. 30 Years of NF-kappaB: A blossoming of relevance 
to human pathobiology. Cell. 2017;168(1-2):37-57
[28] Hayden MS, Ghosh S. NF-kappaB, the first quarter-century: Remarkable progress and 
outstanding questions. Genes & Development. 2012;26(3):203-234
[29] Ben-Neriah Y, Karin M. Inflammation meets cancer, with NF-kappaB as the match-
maker. Nature Immunology. 2011;12(8):715-723
[30] Dondelinger Y et al. Poly-ubiquitination in TNFR1-mediated necroptosis. Cellular and 
Molecular Life Sciences. 2016;73(11-12):2165-2176
[31] Cohen P, Strickson S. The role of hybrid ubiquitin chains in the MyD88 and other innate 
immune signalling pathways. Cell Death and Differentiation. 2017;24(7):1153-1159
[32] Oviedo-Boyso J, Bravo-Patino A, Baizabal-Aguirre VM. Collaborative action of toll-like 
and NOD-like receptors as modulators of the inflammatory response to pathogenic bac-
teria. Mediators of Inflammation. 2014;2014:432785
[33] Morgan MJ, Liu ZG. Crosstalk of reactive oxygen species and NF-kappaB signaling. Cell 
Research. 2011;21(1):103-115
[34] Gutierrez H, Davies AM. Regulation of neural process growth, elaboration and struc-
tural plasticity by NF-kappaB. Trends in Neurosciences. 2011;34(6):316-325
[35] Miyamoto S. Nuclear initiated NF-kappaB signaling: NEMO and ATM take center stage. 
Cell Research. 2011;21(1):116-130
[36] Gupta SC et al. Inhibiting NF-kappaB activation by small molecules as a therapeutic 
strategy. Biochimica et Biophysica Acta. 2010;1799(10-12):775-787
[37] Sadikot RT et al. Selective I kappa B kinase expression in airway epithelium generates 
neutrophilic lung inflammation. Journal of Immunology. 2003;170(2):1091-1098
[38] Aleksic T et al. Cellular immune reaction in the pancreas is induced by constitutively 
active IkappaB kinase-2. Gut. 2007;56(2):227-236
[39] Baumann B et al. Constitutive IKK2 activation in acinar cells is sufficient to induce pan-
creatitis in vivo. The Journal of Clinical Investigation. 2007;117(6):1502-1513
Signaling Pathways Regulating the Pathophysiological Responses of Astrocytes: A Focus on the…
http://dx.doi.org/10.5772/intechopen.72283
29
[40] Maier HJ et al. Cardiomyocyte-specific IkappaB kinase (IKK)/NF-kappaB activation 
induces reversible inflammatory cardiomyopathy and heart failure. Proceedings of the 
National Academy of Sciences of the United States of America. 2012;109(29):11794-11799
[41] Vlantis K et al. Constitutive IKK2 activation in intestinal epithelial cells induces intesti-
nal tumors in mice. The Journal of Clinical Investigation. 2011;121(7):2781-2793
[42] Salem HH et al. Long-term IKK2/NF-kappaB signaling in pancreatic beta-cells induces 
immune-mediated diabetes. Diabetes. 2014;63(3):960-975
[43] Sunami Y et al. Hepatic activation of IKK/NFkappaB signaling induces liver fibrosis via 
macrophage-mediated chronic inflammation. Hepatology. 2012;56(3):1117-1128
[44] Herrmann O et al. IKK mediates ischemia-induced neuronal death. Nature Medicine. 
2005;11(12):1322-1329
[45] van Loo G et al. Inhibition of transcription factor NF-kappaB in the central nervous 
system ameliorates autoimmune encephalomyelitis in mice. Nature Immunology. 
2006;7(9):954-961
[46] Kaltschmidt B, Kaltschmidt C. NF-KappaB in long-term memory and structural plastic-
ity in the adult mammalian brain. Frontiers in Molecular Neuroscience. 2015;8:69
[47] Maqbool A et al. Sustained, neuron-specific IKK/NF-kappaB activation generates a 
selective neuroinflammatory response promoting local neurodegeneration with aging. 
Molecular Neurodegeneration. 2013;8:40
[48] Schmeisser MJ et al. IkappaB kinase/nuclear factor kappaB-dependent insulin-like 
growth factor 2 (Igf2) expression regulates synapse formation and spine maturation via 
Igf2 receptor signaling. The Journal of Neuroscience. 2012;32(16):5688-5703
[49] Lampron A, Elali A, Rivest S. Innate immunity in the CNS: Redefining the relationship 
between the CNS and its environment. Neuron. 2013;78(2):214-232
[50] Santello M, Volterra A. TNFalpha in synaptic function: Switching gears. Trends in 
Neurosciences. 2012;35(10):638-647
[51] Gveric D et al. Transcription factor NF-kappaB and inhibitor I kappaBalpha are local-
ized in macrophages in active multiple sclerosis lesions. Journal of Neuropathology and 
Experimental Neurology. 1998;57(2):168-178
[52] Nonaka M et al. Prolonged activation of NF-kappaB following traumatic brain injury in 
rats. Journal of Neurotrauma. 1999;16(11):1023-1034
[53] Swarup V et al. Deregulation of TDP-43 in amyotrophic lateral sclerosis triggers nuclear 
factor kappaB-mediated pathogenic pathways. The Journal of Experimental Medicine. 
2011;208(12):2429-2447
[54] Hsiao HY et al. A critical role of astrocyte-mediated nuclear factor-kappaB-dependent 
inflammation in Huntington's disease. Human Molecular Genetics. 2013;22(9):1826-1842
Astrocyte - Physiology and Pathology30
[55] Young AM et al. Aberrant NF-kappaB expression in autism spectrum condition: A 
mechanism for neuroinflammation. Frontiers in Psychiatry. 2011;2:27
[56] Brambilla R et al. Inhibition of astroglial nuclear factor kappaB reduces inflammation 
and improves functional recovery after spinal cord injury. The Journal of Experimental 
Medicine. 2005;202(1):145-156
[57] Lattke M et al. Nuclear factor kappaB activation impairs ependymal ciliogenesis and 
links neuroinflammation to hydrocephalus formation. The Journal of Neuroscience. 
2012;32(34):11511-11523
[58] Lattke M et al. Transient IKK2 activation in astrocytes initiates selective non-cell-auton-
omous neurodegeneration. Molecular Neurodegeneration. 2017;12(1):16
[59] Lian H et al. IkappaBalpha deficiency in brain leads to elevated basal neuroinflamma-
tion and attenuated response following traumatic brain injury: Implications for func-
tional recovery. Molecular Neurodegeneration. 2012;7:47
[60] Brambilla R et al. Transgenic inhibition of astroglial NF-kappa B improves functional 
outcome in experimental autoimmune encephalomyelitis by suppressing chronic cen-
tral nervous system inflammation. Journal of Immunology. 2009;182(5):2628-2640
[61] Brambilla R et al. Astrocytes play a key role in EAE pathophysiology by orchestrating 
in the CNS the inflammatory response of resident and peripheral immune cells and by 
suppressing remyelination. Glia. 2014;62(3):452-467
[62] Dvoriantchikova G et al. Inactivation of astroglial NF-kappa B promotes survival 
of retinal neurons following ischemic injury. The European Journal of Neuroscience. 
2009;30(2):175-185
[63] Brambilla R et al. Transgenic inhibition of astroglial NF-kappaB protects from optic 
nerve damage and retinal ganglion cell loss in experimental optic neuritis. Journal of 
Neuroinflammation. 2012;9:213
[64] Oeckl P et al. Astrocyte-specific IKK2 activation in mice is sufficient to induce neuro-
inflammation but does not increase susceptibility to MPTP. Neurobiology of Disease. 
2012;48(3):481-487
[65] Stolp HB, Dziegielewska KM. Review: Role of developmental inflammation and blood-
brain barrier dysfunction in neurodevelopmental and neurodegenerative diseases. 
Neuropathology and Applied Neurobiology. 2009;35(2):132-146
[66] Tsutsui Y, Kosugi I, Kawasaki H. Neuropathogenesis in cytomegalovirus infection: 
Indication of the mechanisms using mouse models. Reviews in Medical Virology. 
2005;15(5):327-345
[67] Bracchi-Ricard V et al. Astroglial nuclear factor-kappaB regulates learning and mem-
ory and synaptic plasticity in female mice. Journal of Neurochemistry. 2008;104(3): 
611-623
Signaling Pathways Regulating the Pathophysiological Responses of Astrocytes: A Focus on the…
http://dx.doi.org/10.5772/intechopen.72283
31
[68] Zhang Y et al. Astrocytic process plasticity and IKKbeta/NF-kappaB in central con-
trol of blood glucose, blood pressure, and body weight. Cell Metabolism. 2017;25(5): 
1091-1102 e4
[69] Custer SK et al. Bergmann glia expression of polyglutamine-expanded ataxin-7 pro-
duces neurodegeneration by impairing glutamate transport. Nature Neuroscience. 
2006;9(10):1302-1311
[70] Lian H et al. NFkappaB-activated astroglial release of complement C3 compromises neu-
ronal morphology and function associated with Alzheimer's disease. Neuron. 2015;85(1): 
101-115
[71] Brambilla R et al. Transgenic inhibition of astroglial NF-kappa B leads to increased 
axonal sparing and sprouting following spinal cord injury. Journal of Neurochemistry. 
2009;110(2):765-778
[72] Wang X et al. Astrocytic A20 ameliorates experimental autoimmune encephalomyelitis 
by inhibiting NF-kappaB- and STAT1-dependent chemokine production in astrocytes. 
Acta Neuropathologica. 2013;126(5):711-724
[73] Raasch J et al. IkappaB kinase 2 determines oligodendrocyte loss by non-cell-autonomous 
activation of NF-kappaB in the central nervous system. Brain. 2011;134(Pt 4):1184-1198
[74] Barakat DJ et al. Astroglial NF-kappaB mediates oxidative stress by regulation of NADPH 
oxidase in a model of retinal ischemia reperfusion injury. Journal of Neurochemistry. 
2012;120(4):586-597
[75] Zhang W et al. Neuronal activation of NF-kappaB contributes to cell death in cerebral 
ischemia. Journal of Cerebral Blood Flow and Metabolism. 2005;25(1):30-40
[76] Jayakumar AR et al. NF-kappaB in the mechanism of brain edema in acute liver failure: 
Studies in transgenic mice. Neurobiology of Disease. 2011;41(2):498-507
[77] Crosio C et al. Astroglial inhibition of NF-kappaB does not ameliorate disease onset 
and progression in a mouse model for amyotrophic lateral sclerosis (ALS). PLoS One. 
2011;6(3):e17187
[78] Ceyzeriat K et al. The complex STATes of astrocyte reactivity: How are they controlled 
by the JAK-STAT3 pathway? Neuroscience. 2016;330:205-218
[79] Namihira M, Nakashima K. Mechanisms of astrocytogenesis in the mammalian brain. 
Current Opinion in Neurobiology. 2013;23(6):921-927
[80] Koyama Y. Signaling molecules regulating phenotypic conversions of astrocytes and glial 
scar formation in damaged nerve tissues. Neurochemistry International. 2014;78:35-42
[81] Laywell ED et al. Identification of a multipotent astrocytic stem cell in the immature 
and adult mouse brain. Proceedings of the National Academy of Sciences of the United 
States of America. 2000;97(25):13883-13888
Astrocyte - Physiology and Pathology32
[82] Hasel P et al. Neurons and neuronal activity control gene expression in astrocytes to 
regulate their development and metabolism. Nature Communications. 2017;8:15132
[83] Ehm O et al. RBPJkappa-dependent signaling is essential for long-term maintenance of 
neural stem cells in the adult hippocampus. The Journal of Neuroscience. 2010;30(41): 
13794-13807
Signaling Pathways Regulating the Pathophysiological Responses of Astrocytes: A Focus on the…
http://dx.doi.org/10.5772/intechopen.72283
33

